ArticleJournal of clinical medicine2019
Medical Cannabis for Older Patients-Treatment Protocol and Initial Results.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.Drugs & aging · 2021Pooled it
- Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review.Trends in psychiatry and psychotherapyPooled it
- Cannabis Use Among People Aged 65 and Older: Results From an Intercept Survey in New York City.Journal of the American Geriatrics Society · 2026Article
- Mortality Trends Associated With Acute Myocardial Infarction and Psychoactive Substance Use in Older Adults: A US Nationwide Analysis (1999-2020).Clinical cardiology · 2025Observational
- Prevalence of Self-Reported Adverse Effects to Cannabis by Older Canadians: A Cross-Sectional Analysis.Drugs & aging · 2025Article
- Cannabis Use Among Older Adults.JAMA network open · 2025Article
- Medical cannabis utilization in children - a study based on a nationwide cohort.Frontiers in pharmacology · 2025Article
- Exploring The Contours: Navigating Cannabis Use Among Older Adults.Journal of Brown hospital medicine · 2024Review
- Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.Frontiers in pharmacology · 2024Article
- Medical Cannabis Use and Its Impact on Health Among Older Adults: Recent Research Findings and Future Directions.Current addiction reports · 2023Article
- Medical Cannabis Is Not Associated with a Decrease in Activities of Daily Living in Older Adults.Biomedicines · 2023Article
- The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer's Disease.Biomolecules · 2023Review
- Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks.Pain and therapy · 2023Review
- Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.Brain sciences · 2022Review
- A Clinical Framework for Assessing Cannabis-Related Impairment Risk.Frontiers in psychiatry · 2022Review
- Cannabis use frequency, route of administration, and co-use with alcohol among older adults in Washington state.Journal of cannabis research · 2021Article
- Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.